drugset / Trial / NCT02465060

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting 6452 enrolled National Cancer Institute (NCI)

Non-randomizedParallel-groupOpen-labelScreening

Summary

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Timeline

Start: 2015-08-17
Primary completion: 2026-12-31
Completion: 2026-12-31

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adavosertib	Small molecule	—	Oral
Subject	Afatinib	Small molecule	—	Oral
Subject	Binimetinib	Small molecule	—	Oral
Subject	Capivasertib	Small molecule	—	Oral
Subject	Copanlisib	Small molecule	60 mg	Intravenous
Subject	Crizotinib	Small molecule	—	Oral
Subject	Dabrafenib	Small molecule	—	Oral
Subject	Defactinib	Small molecule	400 mg	Oral
Subject	Erdafitinib	Small molecule	—	Oral
Subject	Fexagratinib	Small molecule	80 mg	Oral
Subject	GSK2636771	Small molecule	400 mg	Oral
Subject	Ipatasertib	Small molecule	—	Oral
Subject	Larotrectinib	Small molecule	—	Oral
Subject	Nivolumab	Monoclonal antibody	—	Intravenous
Subject	Osimertinib	Small molecule	80 mg	Oral
Subject	Palbociclib	Small molecule	—	Oral
Subject	Pertuzumab	Monoclonal antibody	—	Intravenous
Subject	Relatlimab	Monoclonal antibody	—	Intravenous
Subject	Sapanisertib	Small molecule	—	Oral
Subject	Sunitinib	Small molecule	50 mg	Oral
Subject	Taselisib	Small molecule	4 mg	Oral
Subject	Trametinib	Small molecule	2 mg	Oral
Subject	Trastuzumab	Monoclonal antibody	—	Intravenous
Subject	Trastuzumab emtansine	Other / unclassified	—	Intravenous
Subject	Ulixertinib	Small molecule	—	Oral
Subject	Vismodegib	Small molecule	150 mg	Oral
Subject	dasatinib anhydrous	Small molecule	—	Oral

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Summary

Timeline

Publications

Drugs

Indications